Evoke Pharma Inc (NASDAQ:EVOK) — Market Cap & Net Worth
Market Cap & Net Worth: Evoke Pharma Inc (EVOK)
Evoke Pharma Inc (NASDAQ:EVOK) has a market capitalization of $18.95 Million ($18.95 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25197 globally and #5107 in its home market, demonstrating a -6.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evoke Pharma Inc's stock price $28.10 by its total outstanding shares 1722409 (1.72 Million). Analyse Evoke Pharma Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
Evoke Pharma Inc Market Cap History: 2015 to 2026
Evoke Pharma Inc's market capitalization history from 2015 to 2026. Data shows change from $818.49 Million to $48.40 Million (-24.91% CAGR).
Index Memberships
Evoke Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #727 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2387 of 3165 |
Weight: Evoke Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evoke Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evoke Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.74x
Evoke Pharma Inc's market cap is 0.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $639.91 Million | $23.02K | -$13.15 Million | 27797.98x | N/A |
| 2021 | $136.41 Million | $1.62 Million | -$8.54 Million | 84.31x | N/A |
| 2022 | $55.39 Million | $2.51 Million | -$8.22 Million | 22.08x | N/A |
| 2023 | $21.71 Million | $5.18 Million | -$7.79 Million | 4.19x | N/A |
| 2024 | $7.61 Million | $10.25 Million | -$5.35 Million | 0.74x | N/A |
Competitor Companies of EVOK by Market Capitalization
Companies near Evoke Pharma Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Evoke Pharma Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Evoke Pharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Evoke Pharma Inc's market cap moved from $818.49 Million to $ 48.40 Million, with a yearly change of -24.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $48.40 Million | +26.58% |
| 2025 | $38.24 Million | +402.26% |
| 2024 | $7.61 Million | -64.93% |
| 2023 | $21.71 Million | -60.81% |
| 2022 | $55.39 Million | -59.39% |
| 2021 | $136.41 Million | -78.68% |
| 2020 | $639.91 Million | +59.26% |
| 2019 | $401.80 Million | -34.68% |
| 2018 | $615.11 Million | +9.73% |
| 2017 | $560.54 Million | +11.88% |
| 2016 | $501.01 Million | -38.79% |
| 2015 | $818.49 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Evoke Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.95 Million USD |
| MoneyControl | $18.95 Million USD |
| MarketWatch | $18.95 Million USD |
| marketcap.company | $18.95 Million USD |
| Reuters | $18.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more